CURR looks very well priced to buy at the base level where it is trading right now. We have seen this stock easily climb to the .20 level on just some buyers coming in from time to time. As the company continues to deliver growing sales results from the very successful Seratopical line I don't think there will be any better opportunity to buy or accumulate than what we see here. CURR really has no place to go but up.